Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Pharmexa begins phase I/II trial of therapeutic vaccine for breast cancer in Denmark

July 11, 2001

Ivax boosts immunotoxin program with new agreement

July 11, 2001

PSK evaluated in clinical trials as adjuvant immunochemotherapy in colorectal cancer

July 5, 2001

Combination therapies for certain malignancies discussed by Idec

June 29, 2001

Phase I/II bladder cancer trial shows 59% complete response rate on MCC therapy

June 26, 2001

Phase I/II trial begins for malignant melanoma vaccine

June 26, 2001

Second multicenter phase I/II trial of GVAX for NSCLC

June 22, 2001

Patient enrollment completed in phase III trial of CeaVac

June 21, 2001

MabThera monoclonal antibody approved in Japan

June 21, 2001

ImClone reaches second milestone in phase III evaluation of BEC2

June 19, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.